Active Immunotherapy

This is a type of treatment that helps your immune system fight off diseases. Instead of just giving you a vaccine, doctors might give you special medicines or substances that help your immune system become stronger or more active. This can be used to treat certain cancers or autoimmune diseases.

Therapy

What people using Active Immunotherapy report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Active Immunotherapy

How It Works

Active immunotherapy is treatment that prompts a person's own immune system to recognize and attack a disease. Instead of supplying ready-made immune defenses, such as lab-made antibodies, it gives the body something to react to and lets the immune system build its own response. Ordinary preventive vaccines work this way, but as a treatment the term usually means treating people who already have an illness, most often cancer. Cancer cells can carry substances, called tumor-associated antigens, that normal cells lack or have in smaller amounts, and tumors often find ways to hide from immune attack. A cancer treatment vaccine tries to teach the immune system to spot those antigens and destroy the cells that carry them. Other active approaches are less targeted: they provoke strong inflammation in or around a tumor, or use immune signaling proteins called cytokines, such as interferons and interleukins, to make immune cells more active in general.

Who It's For

In the United States, only a few active immunotherapies are approved for cancer, each for a narrow situation. Sipuleucel-T (Provenge) is for men whose prostate cancer has spread and no longer responds to hormone-lowering treatment, and who have few or no symptoms from it. Talimogene laherparepvec, known as T-VEC (Imlygic), is for melanoma that has come back after surgery, with tumors in or under the skin or in lymph nodes that cannot be removed surgically. BCG (bacillus Calmette-Guérin), a live, weakened bacterium closely related to the one that causes tuberculosis, is placed in the bladder to treat early bladder cancer that has not grown into the bladder muscle, often after the visible tumor has been removed. Many other cancer vaccines, including personalized vaccines designed from the mutations in an individual's tumor, are available only in clinical trials. A result in one cancer does not carry over to another, so whether active immunotherapy makes sense depends on the cancer type, its stage and the treatments already tried.

What It Involves

What treatment looks like depends on the product. Sipuleucel-T is made individually for each patient. About three days before each infusion, the person has leukapheresis, a procedure similar to donating blood in which a machine collects white blood cells and returns the rest of the blood. The cells are sent to a lab, exposed to a prostate cancer protein combined with an immune-stimulating protein, and infused back through a vein over about an hour. The full course is three infusions roughly two weeks apart; if an infusion is missed, another cell collection is needed. T-VEC is injected directly into melanoma tumors that can be seen, felt or located by ultrasound. The second treatment comes three weeks after the first, then every two weeks, and not every tumor can be injected at each visit. In the main trial, people received it for a median of about five months. Injected sites are kept covered with airtight dressings for at least a week after each treatment, longer if they weep or ooze. Bladder BCG is given in a urology clinic through a thin catheter passed into the bladder. The person holds the liquid for about two hours before urinating. A typical course starts with one treatment a week for six weeks, often followed by periodic maintenance treatments over many months. Because BCG is live, the clinic gives instructions for handling urine at home for several hours after each treatment.

What to Expect

Flu-like symptoms are the most common reaction across these treatments: fever, chills, tiredness, nausea and aches. After sipuleucel-T, most people have some infusion reaction, usually mild and gone within about two days; acetaminophen and an antihistamine are given beforehand to reduce it. After T-VEC, these symptoms are most frequent during the first three months, and the injection sites can be sore. After bladder BCG, burning with urination, frequent urges to urinate and bladder discomfort are common. These bladder symptoms typically start a few hours after a treatment, last one to three days and often build with each successive treatment. These treatments rarely produce a quick, visible change. Sipuleucel-T did not slow measurable cancer growth in its trials even though survival improved, so ordinary scans and blood tests may not show its benefit. T-VEC responses, when they occurred, took a median of about four months to appear, and treatment is sometimes continued while lesions grow or new ones appear because a response can come later. BCG is judged by cystoscopy, a camera examination of the bladder, along with urine tests at regular intervals.

What the Evidence Says

Evidence differs sharply from one product to another. For sipuleucel-T, the main randomized trial in 512 men found a median survival (the point by which half the men had died) of 25.8 months, compared with 21.7 months for men given their own unactivated cells as a comparison, roughly four extra months. It did not delay measurable cancer progression in any of its large trials. For T-VEC, about 16 percent of people had tumors shrink and stay smaller for at least six months, compared with about 2 percent of those given a different immune-boosting drug (GM-CSF). T-VEC did not significantly improve overall survival and has no proven effect on cancer that has spread to internal organs. Bladder BCG has the longest record. In the pooled studies behind its approval for carcinoma in situ, an early, flat form of bladder cancer confined to the bladder lining, roughly three quarters of the patients who could be assessed had their cancer disappear on bladder examination, and responses lasted a median of four years or more. Those studies were older and had no comparison group. Beyond these products, therapeutic cancer vaccines have a long history of disappointing results. Vaccines aimed at antigens shared across many people's tumors have not reliably shrunk cancers, and many trials have measured immune markers rather than survival. Personalized vaccines built from an individual tumor's mutations are still investigational. In a large melanoma trial reported in 2026, adding one such mRNA vaccine after surgery to a checkpoint inhibitor (a separate, widely used immunotherapy that releases a brake on immune cells) led to fewer cancer recurrences than the checkpoint inhibitor alone, but the vaccine is not yet approved and has not been shown to help people live longer.

Risks & Considerations

Each product carries its own main risk. Bladder BCG contains live bacteria that can occasionally spread beyond the bladder and cause serious, sometimes fatal infection. A fever that persists, a fever of 103°F or higher, or flu-like illness lasting more than about three days after a treatment should be reported to the urology team right away rather than waited out. Someone who becomes very unwell (confused, faint or struggling to breathe) needs emergency care immediately (call 911). Severe burning, blood in the urine, joint pain, cough or a rash are also worth reporting. BCG is not used in people with a weakened immune system, including from steroids, chemotherapy or conditions such as advanced HIV infection, leukemia or lymphoma, or in people with active tuberculosis. Antibiotics taken around a treatment can reduce its effect. T-VEC is a modified, live herpes virus. Household members, caregivers, sex partners, pregnant women and newborns should avoid contact with injected sites, dressings and body fluids, and anyone exposed who develops cold sores or blisters should contact a clinician. T-VEC is not used in people with a weakened immune system (including from leukemia, lymphoma, advanced HIV infection or immune-suppressing medicines), because the virus can cause a severe, spreading herpes infection, or during pregnancy; people who could become pregnant use effective contraception during treatment. People with an autoimmune disease need a careful discussion first, because the treatment can trigger immune reactions against the body. Sipuleucel-T infusions occasionally cause breathing difficulty, fainting or low blood pressure, so people with heart or lung disease are watched closely. Blood clots and strokes have been reported, mostly in people with other risk factors, and a direct link is uncertain. The repeated cell collections can cause temporary tingling around the mouth, and some people need a central IV line, which carries a risk of infection. The practical commitment is also real: frequent clinic visits, a fixed manufacturing schedule for sipuleucel-T, and for most experimental vaccines, enrollment in a clinical trial with its own eligibility rules.

Questions to Ask Your Doctor

  1. 1.Is an approved active immunotherapy an option for my cancer, and how would it fit with my other treatments?
  2. 2.What benefit can I realistically expect, and how will we know whether it is working if my scans do not change?
  3. 3.Which side effects are likely after each treatment, and which symptoms should I call about right away?
  4. 4.Are there clinical trials of cancer vaccines that I might qualify for?
  5. 5.What precautions do I or the people I live with need to take at home after treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.